Aspen Pharmacare Holdings Limited · JSE:APN

Aspen Pharmacare — Technical Presentation (November 2009)

31 slides from Aspen Pharmacare's technical presentation, Nov 6, 2009

  1. Slide 1: Investors' site visit to Aspen's manufacturing headquarters in Port Elizabeth

    Investors’ site visit to Aspen’s manufacturing headquarters in Port 06 Elizabeth November 2009 Presented by: Dr Morne Geyser, Head of Operations

  2. Slide 2: Transformation of Aspen's manufacturing base

    Transformation of Aspen’s manufacturing base  General Facility has been on the present site for the last 65 years  Acquired by Aspen from SAD in March 1999, together with facilities in EL and JHB  Mainly supplied to the South African market  Within 11 years, Aspen has transformed from a being a

  3. Slide 3: An aerial view of the Port Elizabeth site

    An aerial view of the Port Elizabeth site Technical centre UNIT 3:General Facility UNIT 2: OSD UNIT 1: Packing UNIT 1:OSD UNIT 1: Bottling Plant Steriles Facility: SVP SVP warehouse 3

  4. Slide 4: Regulatory Authorities relevant to South African Operations

    Regulatory Authorities relevant to South African Operations United States EU South Brazil FDA (MRHA) Africa REG AUTHORITY FDA MHRA WHO MCC/PICs ANVISA Aspen Unit 1 (OSD) X X X X X Aspen Unit 2 (OSD) X X Aspen Steriles (SVP) X X Aspen Unit 3 (Gen X Facility) Aspen East London X Aspen Distribution X X

  5. Slide 5: Good Manufacturing Practice Controls (GMP)

    Good Manufacturing Practice Controls (GMP) GMP Compliance Managem Model as implemented ent within Aspen in order Incident to comply with the managem Personnel ent atest International Requirements for Integrated Quality Systems Effective Replaces older Lab Quality Documenta “Rules based” GMP Controls

  6. Slide 6: Aspen-Multinational Partnerships

    Aspen-Multinational Partnerships Boehringe r Nevirapine Ingelheim Lamivudine, Zidovudine & GSK Others Stavudine, Didanosine, BMS Atazanavir Gilead Tenofovir & Emtricitabine MSD Efavirenz Iroko Aldomet and Indocid Cycloserine and Eli Lilly Capreomycin 6

  7. Slide 7: Manufacturing Rationalisation Project

    Manufacturing Rationalisation Project GENERAL FACILITY Complexity reduction End State : Specialised solids packing facility EAST UNIT 1 UNIT 2(a) UNIT 2(b) LONDON High volume domestic + Fluid Bed Oven dried Lennon Dutch export tablets Dried tablets tablets Medicines & & capsules & capsules (LDM) cap

  8. Slide 8: Flow Diagram of the tabletting processes

    Flow Diagram of the tabletting processes Air Dispensing Scale Sievin Fluidised g Bed Dryer Granulat Ai ion Magnesium r Blendi Stearate ng Sievin g Compress ion Packagi ng Coating / Capsule fill 8

  9. Slide 9: Unit 1 - Oral Solid Dosage Facility

    Unit 1 - Oral Solid Dosage Facility  Established 2005  High-volume production of tablets and capsules with a strong focus on:  Key, high-volume tender products  ARV’s – supplied to State, private & export sectors  Licensed products – GSK(ARV’s), Gilead (Truvada, Viread), Iroko (Aldomet, Indocid

  10. Slide 10: Unit 1 - Capacity overview

    Unit 1 - Capacity overview  Unit 1 manufactures 2.4 billion tablets  Investments were made during 2008 and 2009 to increase the capacity in the roller compaction, encapsulation and coating areas, amounting to R20 million. Capacities in each of these areas was doubled  For an additional investment

  11. Slide 11: Unit 2 – Oral Solid Dosage Facility

    Unit 2 – Oral Solid Dosage Facility  New solids manufacturing facility to replace bulk tablet manufacturing in the General Facility  Value of investment is close to R300 million  Small to medium volume solids production for sales into selected regulated  markets, with strong focus on LATAM  Use

  12. Slide 12: An overview of the fluid-bed drying process

    An overview of the fluid-bed drying process  Using the older oven drying technology:  Wet granule obtained during tablet manufacture is dried as a static bed of material spread on trays in an oven  Process time is longer, requiring an average of 8 - 16 hour drying time  The newer fluid bed dryin

  13. Slide 13: Unit 3 – General Facility

    Unit 3 – General Facility  Unit 3 currently comprises the following:  Large range of lower volume solids manufacturing and packing  Large range of liquids and semi-solids (e.g. creams, ointments and suppositories) manufacturing and packing  A phased process for the transfer of products to Unit 1

  14. Slide 14: Sterile Facility (SVP)

    Sterile Facility (SVP)  Specialist facility for the manufacture of eye drops, lyophilised vials and sterile injectables  The Facility will also produce hormonal vials and ampoules – a niche capability to supply female contraceptives and HRT products  Project commenced in 2007, presenting challeng

  15. Slide 15: Maintaining a Sterile Environment

    Maintaining a Sterile Environment HVAC HEPA Filters LAF Canopy Plastic curtain HEPA Filters HEPA Filters Grade A Grade B Grade B Filling Room RAB Enclosed Filling Machine 15

  16. Slide 16: SVP – Multi-Product Suite

    SVP – Multi-Product Suite Lines 1 and 2:  High volume eye drops with an annual capacity of about 50 million units  24 million units to be exported to US and Canada under a manufacturing contract with Prestige Brands  Will introduce Aspen’s range of eye drops – Safyr Bleu, Eyegene, Oculerge Line 3

  17. Slide 17: SVP–Hormonal Injectables

    SVP–Hormonal Injectables Line 4:  High volume ampoule filling capability for hormonal injectables - a niche capability which is very relevant to emerging markets  Commercial production will commence during 2010 with the introduction of Bayer Nur-Isterate for South Africa  Annual capacity for ampo

  18. Slide 18: Aerial view of East London site

    Aerial view of East London site Penicillin Plant Oral Contraceptives General Manufacture 18

  19. Slide 19: East London multi-purpose site

    East London multi-purpose site  Currently highly flexible, small volume, niche, solids manufacture including high potency drugs  To streamline production and focus on manufacturing synergy and cost savings  Close to 1 billion tablets are being produced at East London, approximately 70% of which w

  20. Slide 20: Focus on Continuous Improvement Initiatives

    Focus on Continuous Improvement Initiatives Strategic initiatives:  Rationalisation of capabilities between PE and EL facilities to optimise operational efficiencies and accommodate increasing demand  To achieve economies of scale as volumes are scaled up upon completion of expansion projects  To

  21. Slide 21: Sustainability Initiatives

    Sustainability Initiatives  On-site clinics provide a wide range of health checks, HIV/AIDS counselling and employee support and healthcare awareness programmes  Aspen, through QualSA, provides financial support to employees and their immediate families suffering from HIV/AIDS  A SHE systems deve

  22. Slide 22: Improvement in Recoveries

    Improvement in Recoveries +78% +120% 2007 2008 2009 22

  23. Slide 23: Our employees are invaluable to our business

    Our employees are invaluable to our business and we have made an investment in initiatives to develop, nurture and retain our people to grow and sustain our manufacturing excellence.... 23

  24. Slide 24: Human Resources Philosophy

    Human Resources Philosophy The Group’s HR philosophy aims to promote the following:  Acquisition of talent  Positioning Aspen as an “employer of choice”  Retention of talent  Organisational transformation  A talent pipeline for the future  A strong leadership cadre  A culture of accountabilit

  25. Slide 25: Investing in people - Learning

    Investing in people - Learning  A significant investment has been made in learning and development of both operating and support staff in an attempt to:  Increase the base of scarce skills which are critical to the business  Empower production staff to operate new equipment using improved process

  26. Slide 26: Investing in People - Organisational Development

    Investing in People - Organisational Development  In total 386 employees have undergone psychometric assessments, most of which were conducted for employees at the manufacturing operations  Matches employees’ technical and behavioural competencies to the functional requirements of the job which ar

  27. Slide 27: Pharmacist Assistant Graduates, CIMA Learnership Graduates

    Pharmacist Assistant Graduates CIMA Learnership Graduates Accelerated Development Graduate: Godfrey Keele Pharmacist Interns: Simbongile Pambuka, Lance Geswindt & Bashir Ensoor 27

  28. Slide 28: Prospects in manufacturing: Our Assets

    Prospects in manufacturing  We have built a world-class pharmaceutical manufacturing facility, based on a strong foundation of: A robust MANUFACTURING PROCESS to produce high-quality products OUR Experienced, ASSETS Sophisticated INFRASTRUCT competent and URE with committed diverse PEOPLE capabilit

  29. Slide 29: Prospects in manufacturing (cont.)

    Prospects in manufacturing(cont.)  The investment made in expanding the hard asset base (infrastructure) has been supported by an investment in the soft assets including developing people and enhancing processes  Our cost of manufacturing is competitive against both local and international peers 

  30. Slide 30: From humble beginnings, we have built world-class manufacturing capabilities

    From humble beginnings, we have built world- class manufacturing capabilities and developed a professional and competent team to support Aspen’s transformation into a leading international generics pharmaceutical company, able to deliver in 2010 and beyond... 30

  31. Slide 31: Investors' site visit to Aspen's manufacturing headquarters in Port Elizabeth

    Investors’ site visit to Aspen’s manufacturing headquarters in Port 06 Elizabeth November 2009 Presented by: Dr Morne Geyser, Head of Operations

Aspen Pharmacare Holdings — Technical Presentation (November 2009) on 6ix